Zia Uddin, Shams Suleman, Shah Zeb, Inayat Ullah, Shahabuddin Zia.
Effectiveness of combination therapy with sofosbuvir and daclatasvir in HCV infected patients.
J Med Sci Jan ;28(3):239-43.

Objective: To determine the effectiveness of combination therapy with Sofosbuvir and Daclatasvir in HCV infected patients. Material and Methods: This quasi experimental study spanning over six months from January 2019 till June 2019 was con-ducted in three tertiary care teaching hospitals of Khyber Pakhtunkhwa. A total of 255 RT-PCR confirmed genotype HCV infected patients were included. Combination therapy including standard dose Sofosbuvir (400mg) and Daclatasvir (60mg) regimen for 12 weeks was administered after recording baseline data. The SVR12 (sustained virologic response after 12 weeks) in these patients was observed by repeating the RT-PCR for HCV at 12 weeks after the completion of treatment. Results: This study included 108(42.35 %) male and 147 (57.64 %) female with male to female ratio of 1: 1.36 and Mean age 42.23 +- 11.9 years. Among them 200 (78.4%) were treatment naive and 55 (21.6%) were treatment experienced. A total of 249 patients (97.6%) achieved SVR12 responders and 06 patients (2.4%) failed to achieve SVR12 non-responders. This response to DAA treatment for HCV was clinically and statistically significant. Conclusion: The standard three-month DAA therapy with Sofosbuvir and Daclatasvir for the treatment of HCV has better SVR12 when compared with conventional treatment.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com